| 299.23 3.13 (1.06%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 385.67 | 1-year : | 415.45 |
| Resists | First : | 330.19 | Second : | 355.7 |
| Pivot price | 323.98  |
|||
| Supports | First : | 288.94 | Second : | 240.39 |
| MAs | MA(5) : | 301.49 |
MA(20) : | 328.73 |
| MA(100) : | 323.38 |
MA(250) : | 290.96 |
|
| MACD | MACD : | -10.9 |
Signal : | -6.1 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 8.8 |
| RSI | RSI(14): 29.2 |
|||
| 52-week | High : | 363.79 | Low : | 231.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ WAT ] has closed above bottom band by 14.7%. Bollinger Bands are 101.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 301.32 - 302.76 | 302.76 - 304.07 |
| Low: | 291.12 - 292.82 | 292.82 - 294.36 |
| Close: | 296.45 - 299.22 | 299.22 - 301.74 |
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Mon, 22 Apr 2024
Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns - PR Newswire
Fri, 19 Apr 2024
Waters Corp. stock outperforms competitors on strong trading day - MarketWatch
Thu, 18 Apr 2024
Waters Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Thu, 18 Apr 2024
Is Waters Corporation's (NYSE:WAT) ROE Of 56% Impressive? - Yahoo Finance
Sun, 07 Apr 2024
Is It Too Late To Consider Buying Waters Corporation (NYSE:WAT)? - Simply Wall St
Mon, 11 Mar 2024
Waters Corporation: A Great (Share Price) Run (NYSE:WAT) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 59 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 102 (%) |
| Shares Short | 3,790 (K) |
| Shares Short P.Month | 3,750 (K) |
| EPS | 10.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.44 |
| Profit Margin | 21.7 % |
| Operating Margin | 36.9 % |
| Return on Assets (ttm) | 13.5 % |
| Return on Equity (ttm) | 77.6 % |
| Qtrly Rev. Growth | -4.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 49.9 |
| EBITDA (p.s.) | 17.19 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 603 (M) |
| Levered Free Cash Flow | 444 (M) |
| PE Ratio | 27.6 |
| PEG Ratio | 4.9 |
| Price to Book value | 15.39 |
| Price to Sales | 5.99 |
| Price to Cash Flow | 29.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|